Back

Fibroblast activation in cardio-oncology

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Cardio-oncology: predicting adverse effects and prognosis Cardio-Oncology ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Krithika Loganath

Southampton General Hospital, Southampton (United Kingdom of Great Britain & Northern Ireland)

9 More presentations in this session

Presentation thumbnail
Adverse Myocardial and vascular side effects of Immune Checkpoint Inhibitors: a prospective multimodal cardiovascular assessment (AMICI study)
Doctor M. Mirabel (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Cardiovascular outcomes in acute coronary syndrome patients with cancer: a statewide population-linkage study
Doctor C. Yu (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
The CTOX-Score, a clinical risk prediction tool for cardiovascular toxicity secondary to cancer therapies
Doctor J. Gonzalez Juanatey (Santiago de Compostela, ES)
Abstract Slides Video
Presentation thumbnail
Sodium-glucose co-transporter-2 inhibitors : a potential cardioprotective agent?
Doctor T. Georgopoulou (Heraklion, GR)
Abstract Slides Video
Presentation thumbnail
Disparities in diabetes-related outcomes in prostate cancer patients - role of social determinants of health and race
Doctor A. Guha (Augusta, US)
Abstract Slides Video

Access the full session

Session thumbnail
Cardio-oncology: predicting adverse effects and prognosis

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Myocardial fibroblast imaging with 68GA-FAPI-46 PET/CT in patients with aortic stenosis and preserved left ventricular ejection fraction undergoing aortic valve replacement
thumbnail
Congress Presentation
A novel case of multi-territorial 68Ga-FAPI following acute myocardial infarction
thumbnail
Congress Presentation
Discovery of novel imaging biomarkers for cardiotoxicity in a prospective longitudinal study of cancer patients receiving anthracyclines and chest radiotherapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources